• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Cencora (COR) Has Investors Asking A Bigger Question

    Simply Wall St·10/12/2026 09:26:35
    Listen to the news

    How Cencora Stock Has Been Trading Recently

    Cencora (COR) has been moving on fundamentals rather than a single headline catalyst, with recent trading centered on its pharmaceutical distribution role across U.S. and international healthcare markets.

    The shares last closed at US$323.85, with a small gain over the past day and a modest rise over the past week. Over the past month, performance has been relatively flat, while the past 3 months show a stronger positive return.

    Year to date, the stock is down, in contrast to a positive total return over the past year. Longer horizons look different again, with very large total returns over the past 3 and 5 years that reflect a much higher share price compared with those earlier periods.

    Recent trading suggests momentum in Cencora is cooling slightly in the short term, even though longer horizons still show very strong total shareholder returns, including a 78% three year total shareholder return and 188% over five years.

    Scan beyond Cencora and compare its recent momentum with a curated short list of 31 resilient stocks with low risk scores that pair resilient balance sheets with steadier return profiles.

    Cencora appears to be a solid healthcare distributor with long term returns to match. However, the recent cooling in its share price raises a simple question: are investors now paying a fair price for that strength, or a premium?

    Most Popular Narrative: 12% Undervalued

    Cencora’s most followed narrative puts fair value at about $369 per share, above the last close of $323.85. This frames the recent cooling in the share price very differently from its long run return profile.

    The deepening focus on specialty pharmaceuticals through platforms such as OneOncology and Retina Consultants of America, which are currently performing ahead of initial expectations, positions Cencora to keep growing higher margin services that are likely to matter most for future operating income and earnings.

    The performance of World Courier and European 3PL, which are tied to clinical trial activity and specialty logistics and have recently delivered double digit operating income growth, points to an expanding role for Cencora's international specialty services in driving future revenue and earnings beyond U.S. Healthcare Solutions.

    See why 26 investors see Cencora as 12% undervalued.

    Result: Fair Value of $369 (UNDERVALUED)

    Still, this Cencora narrative can crack if Walgreens-type volume shifts or pressure from lower fee generics and biosimilars hit revenue mix and margins.

    Find out about the key risks to this Cencora narrative.

    Next Steps

    If the mixed tone around Cencora has you on the fence, move quickly, review the data, and weigh the 4 key rewards and 2 important warning signs.

    Looking for more investment ideas beyond Cencora?

    If Cencora has your attention, do not stop here. Use the Simply Wall Street Screener to surface other opportunities that might fit your playbook.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.